IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding 'EDQM issued CEP Certificate for Pantoprazole Sodium Sesquihydrate Process-III '.
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals and Pharmaceuticals has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for Pantoprazole Sodium Sesquihydrate manufactured under Process-III. Pantoprazole Sodium is an active pharmaceutical ingredient (API) widely used in medications for acid reflux and ulcers. The CEP certification is a key regulatory approval required to market and sell this API in European markets. This adds to IOL's portfolio of EDQM-approved APIs and strengthens its export footprint. The approval opens the door to new European pharma customers and contract manufacturing opportunities.
Positive for shareholders — this regulatory approval enables IOL to tap into European demand for Pantoprazole API, supporting future export revenue and product portfolio diversification. Stock could see positive sentiment given the company's growing list of international quality certifications.